Grady, S, Marsh, T, Tenhouse, A, et al. Ketamine for the treatment of major depressive disorder and bipolar depression: a review of the literature. Mental Health Clin. 2017; 7(1): 16–23.
Diaz Granados, N, Ibrahim, L, Brutsche, N, et al. Rapid resolution of suicidal ideation after a single infusion of an N-Methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010; 71(12): 1605–1611.
Newport, DJ, Carpenter, LL, McDonald, WM, et al. Ketamine and other NMDA antagonists: early trials and possible mechanisms in depression. Am J Psychiatry. 2015; 172(10): 950–966.
Kessler, R, Petukhova, M, Sampson, N, et al. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012; 21(3): 169–184.
5.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
Kaufman, J, Charney, D. Comorbidity of mood and anxiety disorders. Depress anxiety. 2000; 12(S1): 69–76.
Fava, M, Rush, A, Alpert, J, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; 165(3): 342–351.
Wiethoff, K, Bauer, M, Baghai, T, et al. Prevalence and treatment outcome in anxious versus nonanxious depression. J Clin Psychiatry. 2010; 71(08): 1047–1054.
Gorman, JM, Kent, JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry. 1999; 60(4): 33–38. discussion, 39.
Roy-Byrne, P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci. 2015; 17(2): 191–206.
Cassano, G, Rossi, N, Pini, S. Psychopharmacology of anxiety disorders. Dialogues Clin Neurosci. 2002; 4(3): 271–285.
Davis, M, Myers, KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002; 52(10): 998–1007.
Madaan, V, Wilson, DR. Neuropeptides: relevance in treatment of depression and anxiety disorders. Drug News Perspect. 2009; 22(6): 319.
Uys, JDK, Stein, DJ, Daniels, WMU. Neuroproteomics: relevance to anxiety disorders. Curr Psychiatry Rep. 2006; 8(4): 286–290.
Duman, RS, Aghajanian, GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012; 338(6103): 68–72.
Trullas, R, Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J. Pharmacol. 1990; 185: 1–10.
Aguado, L, Antonio, AS, Pérez, L, et al. Effects of the NMDA receptor antagonist ketamine on flavor memory: conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol. 1994; 61(3): 271–281.
Garcia, LSB, Comim, CM, Valvassori, SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008; 32(1): 140–144.
Skolnick, P, Layer, R, Popik, P, et al. Adaptation of N-Methyl-D-Aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry. 1996; 29(01): 23–26.
Zarate, CA Jr, Singh, JB, Quiroz, JA, et al. A double-blind, placebo controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006; 163: 153–155.
Autry, AE, Adachi, M, Nosyreva, E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475(7354): 91–95.
Collingridge, GL, Olsen, RW, Peters, J, et al. A nomenclature for ligand-gated ion channels. Neuropharmacology. 2009; 56(1): 2–5.
Monteggia, LM, Gideons, E, Kavalali, ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry. 2013; 73(12): 1199–1203.
Li, N, Liu, R-J, Dwyer, JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011; 69(8): 754–761.
Murrough, JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharmacol Ther. 2011; 91(2): 303–309.
Irwin, SA, Iglewicz, A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med. 2010; 13(7): 903–908.
Irwin, SA, Iglewicz, A, Nelesen, RA, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013; 16(8): 958–965.
Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014; 75(09): e932–e938.
Ballard, ED, Ionescu, DF, Vande Voort, JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014; 58: 161–166.
Goldberg, D, Fawcett, J. The importance of anxiety in both major depression and bipolar disorder. Depress Anxiety. 2012; 29(6): 471–478.
Nock, MK, Hwang, I, Sampson, NA, et al. Mental disorders, comorbidity and suicidal behavior: results from the national comorbidity survey replication. Mol Psychiatry. 2009; 15(8): 868–876.
Ray, SM, Kious, BM. Sustained resolution of panic disorder, agoraphobia, and generalized anxiety disorder with a single ketamine infusion. Prim Care Companion CNS Disord. 2016; 18(4).
Glue, P, Medlicott, NJ, Harland, S, et al. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017; 31(10): 1302–1305.
Glue, P, Neehoff, SM, Medlicott, NJ, et al. Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. J Psychopharmacol. 2018; 32(6): 663–667.
Zarate, CA, Brutsche, NE, Ibrahim, L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012; 71(11): 939–946.
Diazgranados, N, Ibrahim, L, Brutsche, NE, et al. A randomized add-on trial of an n-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8): 793–802.
El-Mallakh, RS, Hollifield, M. Comorbid anxiety in bipolar disorder alters treatment and prognosis. Psychiatr Q. 2008; 79(2): 139–150.
Ionescu, DF, Luckenbaugh, DA, Niciu, MJ, et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2014; 17(4): 438–443.
Grant, BF, Hasin, DS, Blanco, C, et al. The epidemiology of social anxiety disorder in the United States. J Clin Psychiatry. 2005; 66(11): 1351–1361.
Schneier, FR. Social Phobia. Arch Gen Psychiatry. 1992; 49(4): 282–288.
Stein, MB, Liebowitz, MR, Lydiard, RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA. 1998; 280(8): 708.
Katzelnick, D, Kobak, K, Greist, J, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995; 152(9): 1368–1371.
van Vliet, IM, den Boer, JA, Westenberg, HGM. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology. 1994; 115(1
Taylor, JH, Landeros-Weisenberger, A, Coughlin, C, et al. Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology. 2017; 43(2): 325–333.
Haan, E, Oppen, P, Balkom, AJLM, et al. Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand. 1997; 96(5): 354–361.
Eisen, JL, Sibrava, NJ, Boisseau, CL, et al. Five-year course of obsessive-compulsive disorder. J Clin Psychiatry. 2013; 74(03): 233–239.
Skoog, G, Skoog, I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1999; 56(2): 121–127.
Pittenger, C, Bloch, MH, Williams, K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011; 132(3): 314–332.
Adams, TG, Bloch, MH, Pittenger, C. Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2017; 37(2): 269–271.
Bloch, MH, Wasylink, S, Landeros-Weisenberger, A, et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry. 2012; 72(11): 964–970.
Niciu, MJ, Grunschel, BD, Corlett, PR, et al. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive–compulsive disorder and a history of major depressive disorder. J Psychopharmacol. 2013; 27(7): 651–654.
Rodriguez, CI, Kegeles, LS, Levinson, A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013; 38(12): 2475–2483.
Nair, J, Ajit, SS. The role of the glutamatergic system in posttraumatic stress disorder. CNS Spectr. 2008; 13(07): 585–59.
Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, et al. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018; 32(5): 411–420.
Schönenberg, M, Reichwald, U, Domes, G, et al. Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology. 2005; 182(3): 420–425.
Schönenberg, M, Reichwald, U, Domes, G, et al. Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol. 2008; 22(5): 493–497.
McGhee, LL, Maani, CV, Garza, TH, et al. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma. 2008; 64(Supplement): S195–S199.
D’Andrea, D, Andrew Sewell, R. Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion. Biol Psychiatry. 2013; 74(9): e13–e14.
Feder, A, Parides, MK, Murrough, JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014; 71(6): 681–688.
Zeng, MC, Niciu, MJ, Luckenbaugh, DA, et al. Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry. 2013; 73(12): e37–e38.
Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry. 2018; 79(3).
Gollan, JK, Fava, M, Kurian, B, et al. What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety. 2011; 29(2): 94–101.
Malhi, GS, Byrow, Y, Cassidy, F, et al. Ketamine: stimulating antidepressant treatment? BJPsych Open. 2016; 2(03): e5–e9.
Suleiman, Z, Kolawole, I, Bolaji, B. Evaluation of cardiovascular stimulation effects after induction of anaesthesia with ketamine. J West Afr Coll Surg. 2012; 2(1): 38–52.
Castle, C, Gray, A, Neehoff, S, et al. Effect of ketamine dose on self-rated dissociation in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017; 31(10): 1306–1311.
Serafini, G, Howland, R, Rovedi, F, et al. The role of ketamine in treatment-resistant depression: a systematic review. Curr Neuropharmacol. 2014; 12(5): 444–461.
Katalinic, N, Lai, R, Somogyi, A, et al. Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013; 47(8): 710–727.
Girish, B, Prutha, D, Prahlad, P. Ketamine-induced affective switch in a patient with treatment-resistant depression. Indian J Pharmacol. 2015; 47(4): 454–455.
Wan, L-B, Levitch, CF, Perez, AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2014; 76(03): 247–252.
Krishnan, V, Nestler, EJ. The molecular neurobiology of depression. Nature. 2008; 455(7215): 894–902.
Riaza Bermudo-Soriano, C, Perez-Rodriguez, MM, Vaquero-Lorenzo, C, et al. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012; 100(4): 752–774.
Mathew, AR, Pettit, JW, Lewinsohn, PM, et al. Co-morbidity between major depressive disorder and anxiety disorders: shared etiology or direct causation? Psychol Med. 2011; 41(10): 2023–2034.